Meritage Portfolio Management Has $1.93 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Meritage Portfolio Management increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,803 shares of the specialty pharmaceutical company's stock after purchasing an additional 10,622 shares during the quarter. Meritage Portfolio Management owned approximately 0.11% of Supernus Pharmaceuticals worth $1,926,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Supernus Pharmaceuticals by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after purchasing an additional 1,083 shares during the period. Two Sigma Advisers LP lifted its stake in Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after acquiring an additional 1,000 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 870 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Supernus Pharmaceuticals by 6.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after acquiring an additional 3,495 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after acquiring an additional 6,867 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, June 21st.

Supernus Pharmaceuticals Trading Down 1.7%

SUPN traded down $0.53 during trading on Monday, hitting $31.45. The stock had a trading volume of 682,248 shares, compared to its average volume of 479,026. The firm has a market cap of $1.76 billion, a PE ratio of 28.33 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.94 and a 12 month high of $40.28. The company has a 50 day simple moving average of $32.24 and a 200-day simple moving average of $33.81.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.